A
AVIDITY BIOSCIENCES INC
NASDAQ: RNA (Avidity Biosciences, Inc.)
最近更新时间: 12小时之前27.05
-1.36 (-4.79%)
| 前收盘价格 | 28.41 |
| 收盘价格 | 28.79 |
| 成交量 | 1,626,864 |
| 平均成交量 (3个月) | 1,172,631 |
| 市值 | 3,227,308,288 |
| 价格/销量 (P/S) | 372.40 |
| 股市价格/股市净资产 (P/B) | 3.04 |
| 52周波幅 | |
| 利润日期 | 26 Feb 2025 - 3 Mar 2025 |
| 营业利益率 (TTM) | -4,200.94% |
| 稀释每股收益 (EPS TTM) | -2.88 |
| 季度收入增长率 (YOY) | -17.10% |
| 总债务/股东权益 (D/E MRQ) | 0.51% |
| 流动比率 (MRQ) | 17.76 |
| 营业现金流 (OCF TTM) | -184.50 M |
| 杠杆自由现金流 (LFCF TTM) | -135.19 M |
| 资产报酬率 (ROA TTM) | -18.33% |
| 股东权益报酬率 (ROE TTM) | -27.76% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Avidity Biosciences, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.0
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.00 |
|
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 4.83% |
| 机构持股比例 | 106.49% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 78.00 (TD Cowen, 188.36%) | 购买 |
| 中 | 67.00 (147.69%) | |
| 低 | 60.00 (Needham, 121.81%) | 购买 |
| 平均值 | 68.40 (152.87%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 44.99 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Jan 2025 | 72.00 (166.17%) | 购买 | 29.46 |
| 20 Dec 2024 | 72.00 (166.17%) | 购买 | 31.82 | |
| RBC Capital | 26 Nov 2024 | 67.00 (147.69%) | 购买 | 43.80 |
| Chardan Capital | 13 Nov 2024 | 65.00 (140.30%) | 购买 | 52.50 |
| 30 Oct 2024 | 65.00 (140.30%) | 购买 | 43.22 | |
| Needham | 13 Nov 2024 | 60.00 (121.81%) | 购买 | 52.50 |
| 31 Oct 2024 | 60.00 (121.81%) | 购买 | 42.26 | |
| TD Cowen | 21 Oct 2024 | 78.00 (188.35%) | 购买 | 46.71 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合